EP Patent

EP2289510A1 — Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes

Assigned to Xenon Pharmaceuticals Inc · Expires 2011-03-02 · 15y expired

What this patent protects

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where x, y, G, J, K, L, M, W, V, R 2 , R 3 , R 5 , R 5a , R 6 , R 6a , …

USPTO Abstract

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where x, y, G, J, K, L, M, W, V, R 2 , R 3 , R 5 , R 5a , R 6 , R 6a , R 7 , R 7a , R 8 and R 8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
EP2289510A1
Jurisdiction
EP
Classification
Expires
2011-03-02
Drug substance claim
No
Drug product claim
No
Assignee
Xenon Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.